ME02875B - Inhibitori hcv polimeraze - Google Patents
Inhibitori hcv polimerazeInfo
- Publication number
- ME02875B ME02875B MEP-2017-229A MEP2017229A ME02875B ME 02875 B ME02875 B ME 02875B ME P2017229 A MEP2017229 A ME P2017229A ME 02875 B ME02875 B ME 02875B
- Authority
- ME
- Montenegro
- Prior art keywords
- compound according
- c6alkyl
- pharmaceutically acceptable
- solvate
- acceptable salt
- Prior art date
Links
- 229940124683 HCV polymerase inhibitor Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 14
- 150000003839 salts Chemical class 0.000 claims 5
- 239000012453 solvate Substances 0.000 claims 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 3
- -1 hydroxyC1-C6alkyl Chemical group 0.000 claims 3
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 2
- 125000006176 2-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 claims 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 125000001475 halogen functional group Chemical group 0.000 claims 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 1
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 claims 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 1
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 239000003443 antiviral agent Substances 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 208000010710 hepatitis C virus infection Diseases 0.000 claims 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 238000011282 treatment Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/073—Pyrimidine radicals with 2-deoxyribosyl as the saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
- C07H19/11—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids containing cyclic phosphate
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/173—Purine radicals with 2-deoxyribosyl as the saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
- C07H19/213—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids containing cyclic phosphate
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H23/00—Compounds containing boron, silicon or a metal, e.g. chelates or vitamin B12
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Peptides Or Proteins (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Hydrogenated Pyridines (AREA)
Claims (14)
- l. Jedinjenje predstavljeno formulom 1: u kome:B je nukleobaza: u kojoj R7 i R8 su oba H;R1 je: R2 jeR14 je fenil koji je izborno supstituisan sa l , 2 ili 3 R22;jedan od R15 i R15' je H i drugi je C1-C3alkil; R16je C1-C3alkil;svaki R22 je nezavisno izabran od halo, C1-C6alkil, C2-C6alkenil, C1-C6haloalkil, fenil, hidroksiC1-C6alkil, C3-C6cikloalkil,C1-C6alkilkarbonil, C3-C6cikloalkilkarbonil, karboksiC1-C6alkil, okso, OR20, SR20, N(R20)2, CN, NO2, C(O)OR20, C(O)N(R20)2 i NHC(O)R20, ili bilo koje dve R22 grupe vezane za susedne atome ugljenika u prstenu se kombinuju tako da formiraju -O-R23-O-;svaki R20 je nezavisno H, -C,-C6alkil, C1-C6haloalkil, C3-C 7cikloalkil, C1-C6hidroksialkil ili C3-C7cikloalkilC1-C3alkil; R23 je -[C(R33)2]n-;R24 je H;svaki R33je nezavisno izabran od H i C1-C6alkil;U jeO;ili njegova farmaceutski prihvatljiva so i/ili solvat.
- 2. Jedinjenje prema patentnom zahtevu l, naznačeno time što R14 je fenil koji je izborno supstituisan sa jednim ili dva R22pri čemu je svaki R22 nezavisno izabran od halo, C1-C6alkil, C2-C6alkenil i OR20 i R20 je C1-C6alkil.
- 3. Jedinjenje prema patentnom zahtevu 1, naznačeno time što R14 je fenil koji je supstituisan sa dva R22 locirana na susednim atomima ugljenika i dva R22 se kombinuju tako da formiraju O-CH2-O-, na taj način formirajući delimičnu strukturu:
- 4. Jedinjenje prema bilo kom od patentnih zahteva l do 3, naznačeno time što jedan od R15i R15' je H i drugi je metil.
- 5. Jedinjenje prema bilo kom od patentnih zahteva l do 4, naznačeno time što R 16 je metil, etil, propil ili izopropil, poželjno izopropil.
- 6. Jedinjenje prema bilo kom od patentnih zahteva l do 4, naznačeno time što R16 je 2-etilbutil, 2-pentil, 2-butil, izobutil ili terc-pentil, poželjno 2-etilbutil.
- 7. Jedinjenje prema patentnom zahtevu l koje je: ili njegova farmaceutski prihvatljiva so i/ili solvat.
- 8. Jedinjenje prema patentnom zahtevu l koje je:ili njegova farmaceutski prihvatljiva so i/ili solvat.
- 9. Jedinjenje prema patentnom zahtevu l koje je:ili njegova farmaceutski prihvatljiva so i/ili solvat.
- 10. Jedinjenje prema patentnom zahtevu l koje je:ili njegova farmaceutski prihvatljiva so i/ili solvat.
- 11. Jedinjenje prema bilo kom od patentnih zahteva l do 10, za upotrebu kao lek.
- 12. Jedinjenje prema bilo kom od patentnih zahteva l do l0, za upotrebu u lečenju ili profilaksi infekcije virusom hepatitisa C.
- 13. Farmaceutska kompozicija koja sadrži jedinjenje prema bilo kom od patentnih zahteva l do l0 zajedno sa farmaceutski prihvatljivim ađuvansom, razblaživačem ili nosačem.
- 14. Farmaceutska kompozicija koja sadrži jedinjenje prema bilo kom od patentnih zahteva l do l0, koja dodatno sadrži jedno ili više dodatnih drugih antivirusnih sredstava.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE1351026 | 2013-09-04 | ||
| SE1351169 | 2013-10-03 | ||
| SE1450152 | 2014-02-12 | ||
| PCT/SE2014/051005 WO2015034420A1 (en) | 2013-09-04 | 2014-09-02 | Hcv polymerase inhibitors |
| EP14789434.9A EP3041855B1 (en) | 2013-09-04 | 2014-09-02 | Hcv polymerase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME02875B true ME02875B (me) | 2018-04-20 |
Family
ID=52628746
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2017-229A ME02875B (me) | 2013-09-04 | 2014-09-02 | Inhibitori hcv polimeraze |
Country Status (28)
| Country | Link |
|---|---|
| US (5) | US9481703B2 (me) |
| EP (2) | EP3252066B1 (me) |
| JP (2) | JP6456958B2 (me) |
| KR (1) | KR20160078337A (me) |
| CN (3) | CN108558973A (me) |
| AU (2) | AU2014315715B2 (me) |
| BR (1) | BR112016004919A2 (me) |
| CA (1) | CA2921899A1 (me) |
| CL (2) | CL2016000493A1 (me) |
| CR (1) | CR20160123A (me) |
| CY (1) | CY1119587T1 (me) |
| DK (1) | DK3041855T3 (me) |
| EA (1) | EA028974B1 (me) |
| HR (1) | HRP20171435T1 (me) |
| HU (1) | HUE036365T2 (me) |
| IL (2) | IL244389B (me) |
| ME (1) | ME02875B (me) |
| MX (1) | MX2016002849A (me) |
| MY (1) | MY177804A (me) |
| PH (2) | PH12016500402B1 (me) |
| PL (1) | PL3041855T3 (me) |
| PT (1) | PT3041855T (me) |
| RS (1) | RS56383B1 (me) |
| SA (1) | SA516370684B1 (me) |
| SG (2) | SG10201700647PA (me) |
| SI (1) | SI3041855T1 (me) |
| UA (1) | UA117375C2 (me) |
| WO (1) | WO2015034420A1 (me) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9676797B2 (en) | 2015-09-02 | 2017-06-13 | Abbvie Inc. | Anti-viral compounds |
| PL2480559T3 (pl) | 2009-09-21 | 2013-11-29 | Gilead Sciences Inc | Sposoby i związki pośrednie do wytwarzania analogów 11cyjanokarbanukleozydowych |
| WO2012012776A1 (en) | 2010-07-22 | 2012-01-26 | Gilead Sciences, Inc. | Methods and compounds for treating paramyxoviridae virus infections |
| CN104151360B (zh) * | 2013-05-14 | 2019-02-22 | 北京美倍他药物研究有限公司 | 磷酸/膦酸衍生物及其医药用途 |
| UA117375C2 (uk) * | 2013-09-04 | 2018-07-25 | Медівір Аб | Інгібітори полімерази hcv |
| EP3074399A1 (en) * | 2013-11-27 | 2016-10-05 | Idenix Pharmaceuticals LLC | 2'-dichloro and 2'-fluoro-2'-chloro nucleoside analogues for hcv infection |
| EP3074411A2 (en) | 2013-11-27 | 2016-10-05 | Idenix Pharmaceuticals LLC | Nucleotides for the treatment of liver cancer |
| US20170037078A1 (en) * | 2014-04-24 | 2017-02-09 | Cocrystal Pharma, Inc. | 2' -disubstituted nucleoside analogs for treatment of the flaviviridae family of viruses and cancer |
| CN105315319B (zh) * | 2014-07-30 | 2020-11-20 | 南京圣和药业股份有限公司 | 丙型肝炎病毒抑制剂及其应用 |
| TWI767201B (zh) * | 2014-10-29 | 2022-06-11 | 美商基利科學股份有限公司 | 絲狀病毒科病毒感染之治療 |
| US10252989B2 (en) | 2014-12-30 | 2019-04-09 | Dow Agrosciences Llc | Picolinamides with fungicidal activity |
| KR102805798B1 (ko) | 2014-12-30 | 2025-05-15 | 코르테바 애그리사이언스 엘엘씨 | 살진균 활성을 갖는 피콜린아미드 화합물 |
| NZ732649A (en) | 2014-12-30 | 2019-01-25 | Dow Agrosciences Llc | Picolinamides and related compounds |
| WO2016109288A1 (en) * | 2014-12-30 | 2016-07-07 | Dow Agrosciences Llc | Use of picolinamide compounds with fungicidal activity |
| WO2016134057A1 (en) * | 2015-02-18 | 2016-08-25 | Abbvie Inc. | Anti-viral compounds |
| EA201791848A1 (ru) * | 2015-03-02 | 2018-03-30 | Медивир Аб | Композиция фосфорамидата нуклеотида |
| WO2016140615A1 (en) * | 2015-03-02 | 2016-09-09 | Medivir Ab | Nucleotide derivatives which are hcv inhibitors for use in the treatment of hepatitis c |
| WO2016160646A1 (en) * | 2015-04-02 | 2016-10-06 | Merck Sharp & Dohme Corp. | Process for making phosphoramidate protected nucleoside compounds |
| CN107709344B (zh) * | 2015-05-01 | 2022-07-15 | 共晶制药股份有限公司 | 用于治疗黄病毒科病毒和癌症的核苷类似物 |
| WO2017040896A1 (en) * | 2015-09-02 | 2017-03-09 | Abbvie Inc. | Anti-viral compounds |
| WO2017040889A1 (en) * | 2015-09-02 | 2017-03-09 | Abbvie Inc. | Anti-viral compounds |
| WO2017040892A1 (en) * | 2015-09-02 | 2017-03-09 | Abbvie Inc. | Anti-viral compounds |
| WO2017040898A1 (en) * | 2015-09-02 | 2017-03-09 | Abbvie Inc. | Anti-viral compounds |
| WO2017040895A1 (en) * | 2015-09-02 | 2017-03-09 | Abbvie Inc. | Anti-viral compounds |
| EP4088718A1 (en) | 2015-09-16 | 2022-11-16 | Gilead Sciences, Inc. | Methods for treating coronaviridae virus infections |
| CN105367505A (zh) * | 2015-12-01 | 2016-03-02 | 苏利制药科技江阴有限公司 | 一种新型合成3,6-二甲基-2,5-哌嗪二酮的方法 |
| AU2017208970A1 (en) | 2016-01-18 | 2018-08-02 | Arisan Therapeutics | Adamatane derivatives for the treatment of filovirus infection |
| CA3033858A1 (en) * | 2016-08-19 | 2018-02-22 | Sandoz Ag | Sofosbuvir derivatives for the treatment of hepatitis c |
| CN116036112A (zh) | 2017-03-14 | 2023-05-02 | 吉利德科学公司 | 治疗猫冠状病毒感染的方法 |
| KR20190141747A (ko) | 2017-05-01 | 2019-12-24 | 길리애드 사이언시즈, 인코포레이티드 | (S)-2-에틸부틸 2-(((S)-(((2R,3S,4R,5R)-5-(4-아미노피롤로[2,1-f] [1,2,4]트리아진-7-일)-5-시아노-3,4-디히드록시테트라히드로푸란-2-일)메톡시)(페녹시) 포스포릴)아미노)프로파노에이트의 결정질 형태 |
| CA3062074A1 (en) | 2017-05-02 | 2018-11-08 | Dow Agrosciences Llc | Use of an acyclic picolinamide compound as a fungicide for fungal diseases on turfgrasses |
| TWI774761B (zh) | 2017-05-02 | 2022-08-21 | 美商科迪華農業科技有限責任公司 | 用於穀物中的真菌防治之協同性混合物 |
| TW201842851A (zh) | 2017-05-02 | 2018-12-16 | 美商陶氏農業科學公司 | 用於穀類中的真菌防治之協同性混合物 |
| US10675296B2 (en) | 2017-07-11 | 2020-06-09 | Gilead Sciences, Inc. | Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections |
| US11548893B2 (en) | 2017-07-15 | 2023-01-10 | Arisan Therapeutics Inc. | Enantiomerically pure adamantane carboxamides for the treatment of filovirus infection |
| BR102019004480B1 (pt) | 2018-03-08 | 2023-03-28 | Dow Agrosciences Llc | Picolinamidas como fungicidas |
| US12221459B2 (en) | 2018-03-09 | 2025-02-11 | Medivir Ab | Cancer treatment with (2,2-bishydroxymethyl) methylenecyclopropane nucleotides |
| JP2022512697A (ja) | 2018-10-15 | 2022-02-07 | コルテバ アグリサイエンス エルエルシー | オキシピコリンアミドの合成のための方法 |
| CN109762040A (zh) * | 2019-01-14 | 2019-05-17 | 歌礼生物制药(杭州)有限公司 | 一种核苷类ns5b聚合酶抑制剂的制备方法 |
| US12281076B2 (en) | 2019-10-18 | 2025-04-22 | Corteva Agriscience Llc | Process for synthesis of picolinamides |
| US11660307B2 (en) | 2020-01-27 | 2023-05-30 | Gilead Sciences, Inc. | Methods for treating SARS CoV-2 infections |
| US10874687B1 (en) | 2020-02-27 | 2020-12-29 | Atea Pharmaceuticals, Inc. | Highly active compounds against COVID-19 |
| CN111269263A (zh) * | 2020-03-09 | 2020-06-12 | 上海龙翔生物医药开发有限公司 | 一种瑞德西韦侧链中间体及其制备方法 |
| CA3169340A1 (en) | 2020-03-12 | 2021-09-16 | Pavel R. Badalov | Methods of preparing 1'-cyano nucleosides |
| CN115362004B (zh) | 2020-04-06 | 2026-01-09 | 吉利德科学公司 | 1’-氰基取代的碳核苷类似物的吸入制剂 |
| CN111848679A (zh) * | 2020-04-17 | 2020-10-30 | 山东科巢生物制药有限公司 | 一种利用微通道反应技术合成瑞德西韦的方法 |
| WO2021243157A1 (en) | 2020-05-29 | 2021-12-02 | Gilead Sciences, Inc. | Remdesivir treatment methods |
| US11939347B2 (en) | 2020-06-24 | 2024-03-26 | Gilead Sciences, Inc. | 1′-cyano nucleoside analogs and uses thereof |
| PT4204421T (pt) | 2020-08-27 | 2024-06-25 | Gilead Sciences Inc | Compostos e métodos para o tratamento de infeções virais |
| US12274700B1 (en) | 2020-10-30 | 2025-04-15 | Accencio LLC | Methods of treating symptoms of coronavirus infection with RNA polymerase inhibitors |
| TWI867455B (zh) | 2022-03-02 | 2024-12-21 | 美商基利科學股份有限公司 | 用於治療病毒感染的化合物及方法 |
| US12357577B1 (en) | 2024-02-02 | 2025-07-15 | Gilead Sciences, Inc. | Pharmaceutical formulations and uses thereof |
| CN116199679A (zh) * | 2022-12-23 | 2023-06-02 | 吉斯凯(苏州)制药有限公司 | 一种拉米夫定的工业化制备方法 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69331643T2 (de) | 1992-12-29 | 2002-10-31 | Abbott Laboratories, Abbott Park | Zwischenprodukte zur Herstellung retroviraler proteasehemmenden Verbindungen |
| IL110752A (en) | 1993-09-13 | 2000-07-26 | Abbott Lab | Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor |
| US5559158A (en) | 1993-10-01 | 1996-09-24 | Abbott Laboratories | Pharmaceutical composition |
| IL111991A (en) | 1994-01-28 | 2000-07-26 | Abbott Lab | Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent |
| US6037157A (en) | 1995-06-29 | 2000-03-14 | Abbott Laboratories | Method for improving pharmacokinetics |
| KR100905221B1 (ko) * | 2000-10-18 | 2009-07-01 | 파마셋 인코포레이티드 | 바이러스 감염 및 비정상적인 세포 증식의 치료를 위한변형된 뉴클레오시드 |
| PE20070211A1 (es) | 2005-07-29 | 2007-05-12 | Medivir Ab | Compuestos macrociclicos como inhibidores del virus de hepatitis c |
| US20090298708A1 (en) * | 2006-08-23 | 2009-12-03 | Masad Damha J | 2'-deoxy-2'-fluoro-beta-d-arabinonucleoside 5'-triphosphates and their use in enzymatic nucleic acid synthesis |
| CN101979397B (zh) * | 2006-10-10 | 2013-11-06 | 美迪维尔公司 | Hcv核苷类抑制剂 |
| US20080261913A1 (en) | 2006-12-28 | 2008-10-23 | Idenix Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of liver disorders |
| US7964580B2 (en) * | 2007-03-30 | 2011-06-21 | Pharmasset, Inc. | Nucleoside phosphoramidate prodrugs |
| CN102137676A (zh) | 2007-12-27 | 2011-07-27 | 伊皮芬尼生物科学公司 | 抗病毒化合物 |
| US8173621B2 (en) * | 2008-06-11 | 2012-05-08 | Gilead Pharmasset Llc | Nucleoside cyclicphosphates |
| AU2009329872B2 (en) | 2008-12-23 | 2016-07-07 | Gilead Pharmasset Llc | Synthesis of purine nucleosides |
| WO2010108140A1 (en) * | 2009-03-20 | 2010-09-23 | Alios Biopharma, Inc. | Substituted nucleoside and nucleotide analogs |
| CN101591371B (zh) * | 2009-06-30 | 2012-05-30 | 连云港金康医药科技有限公司 | 一种通过卤交换氟化制备吉西他滨或其类似物的方法 |
| SI2609923T1 (sl) | 2010-03-31 | 2017-10-30 | Gilead Pharmasset Llc | Postopek za kristalizacijo (s)-izopropil 2-(((s)-(perfluorofenoksi) (fenoksi)fosforil)amino)propanoata |
| US8402690B2 (en) | 2010-09-09 | 2013-03-26 | Sterling International Inc. | Bedbug trap |
| US20120070411A1 (en) * | 2010-09-22 | 2012-03-22 | Alios Biopharma, Inc. | Substituted nucleotide analogs |
| CN103209987B (zh) * | 2010-09-22 | 2017-06-06 | 艾丽奥斯生物制药有限公司 | 取代的核苷酸类似物 |
| WO2012142085A1 (en) | 2011-04-13 | 2012-10-18 | Merck Sharp & Dohme Corp. | 2'-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases |
| US9403863B2 (en) | 2011-09-12 | 2016-08-02 | Idenix Pharmaceuticals Llc | Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections |
| SI2794627T1 (sl) | 2011-12-22 | 2019-02-28 | Alios Biopharma, Inc. | Substituirani nukleozidi, nukleotidi in njihovi analogi |
| EP2920195A1 (en) | 2012-11-14 | 2015-09-23 | IDENIX Pharmaceuticals, Inc. | D-alanine ester of rp-nucleoside analog |
| UA117375C2 (uk) * | 2013-09-04 | 2018-07-25 | Медівір Аб | Інгібітори полімерази hcv |
| EP3074411A2 (en) * | 2013-11-27 | 2016-10-05 | Idenix Pharmaceuticals LLC | Nucleotides for the treatment of liver cancer |
| EP3074399A1 (en) * | 2013-11-27 | 2016-10-05 | Idenix Pharmaceuticals LLC | 2'-dichloro and 2'-fluoro-2'-chloro nucleoside analogues for hcv infection |
| US20170037078A1 (en) | 2014-04-24 | 2017-02-09 | Cocrystal Pharma, Inc. | 2' -disubstituted nucleoside analogs for treatment of the flaviviridae family of viruses and cancer |
-
2014
- 2014-02-09 UA UAA201602085A patent/UA117375C2/uk unknown
- 2014-09-02 CN CN201810473163.XA patent/CN108558973A/zh active Pending
- 2014-09-02 AU AU2014315715A patent/AU2014315715B2/en not_active Ceased
- 2014-09-02 CN CN201480060874.4A patent/CN105705510B/zh active Active
- 2014-09-02 HR HRP20171435TT patent/HRP20171435T1/hr unknown
- 2014-09-02 EP EP17176973.0A patent/EP3252066B1/en active Active
- 2014-09-02 MX MX2016002849A patent/MX2016002849A/es unknown
- 2014-09-02 KR KR1020167008381A patent/KR20160078337A/ko not_active Withdrawn
- 2014-09-02 JP JP2016540848A patent/JP6456958B2/ja active Active
- 2014-09-02 HU HUE14789434A patent/HUE036365T2/hu unknown
- 2014-09-02 SG SG10201700647PA patent/SG10201700647PA/en unknown
- 2014-09-02 ME MEP-2017-229A patent/ME02875B/me unknown
- 2014-09-02 EA EA201690452A patent/EA028974B1/ru not_active IP Right Cessation
- 2014-09-02 WO PCT/SE2014/051005 patent/WO2015034420A1/en not_active Ceased
- 2014-09-02 DK DK14789434.9T patent/DK3041855T3/en active
- 2014-09-02 PT PT147894349T patent/PT3041855T/pt unknown
- 2014-09-02 BR BR112016004919A patent/BR112016004919A2/pt not_active Application Discontinuation
- 2014-09-02 MY MYPI2016700722A patent/MY177804A/en unknown
- 2014-09-02 SI SI201430401T patent/SI3041855T1/sl unknown
- 2014-09-02 CN CN201810472644.9A patent/CN108676047B/zh active Active
- 2014-09-02 PL PL14789434T patent/PL3041855T3/pl unknown
- 2014-09-02 CA CA2921899A patent/CA2921899A1/en not_active Abandoned
- 2014-09-02 EP EP14789434.9A patent/EP3041855B1/en active Active
- 2014-09-02 RS RS20170949A patent/RS56383B1/sr unknown
- 2014-09-02 SG SG11201601474UA patent/SG11201601474UA/en unknown
-
2015
- 2015-02-27 US US14/634,449 patent/US9481703B2/en active Active
-
2016
- 2016-02-29 PH PH12016500402A patent/PH12016500402B1/en unknown
- 2016-03-02 IL IL244389A patent/IL244389B/en not_active IP Right Cessation
- 2016-03-03 CL CL2016000493A patent/CL2016000493A1/es unknown
- 2016-03-06 SA SA516370684A patent/SA516370684B1/ar unknown
- 2016-03-10 CR CR20160123A patent/CR20160123A/es unknown
- 2016-07-14 US US15/210,500 patent/US9540411B2/en not_active Expired - Fee Related
- 2016-11-23 US US15/360,360 patent/US9828408B2/en not_active Expired - Fee Related
-
2017
- 2017-06-13 AU AU2017203954A patent/AU2017203954B2/en not_active Ceased
- 2017-10-04 CY CY20171101032T patent/CY1119587T1/el unknown
- 2017-11-27 US US15/823,224 patent/US10106571B2/en not_active Expired - Fee Related
-
2018
- 2018-05-02 PH PH12018500931A patent/PH12018500931A1/en unknown
- 2018-09-12 IL IL261702A patent/IL261702B/en not_active IP Right Cessation
- 2018-10-12 JP JP2018193251A patent/JP2019065011A/ja not_active Ceased
- 2018-10-22 US US16/166,578 patent/US20190085010A1/en not_active Abandoned
-
2019
- 2019-02-01 CL CL2019000271A patent/CL2019000271A1/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ME02875B (me) | Inhibitori hcv polimeraze | |
| HRP20200648T1 (hr) | Derivati sulfamoilpirolamida i njihova uporaba kao lijekova za liječenje hepatitisa b | |
| HRP20211224T1 (hr) | Derivati pirimidina za liječenje virusnih infekcija | |
| HRP20180791T1 (hr) | Glioksamid supstituirani derivati pirolamida i njihova uporaba kao lijekova za liječenje hepatitisa b | |
| ME02835B (me) | Antivirusna rsv jedinjenja | |
| HRP20221112T1 (hr) | Derivati benzodiazepina kao inhibitori rsv | |
| HRP20211728T1 (hr) | Rsv antivirusni pirazolo- i triazolo-pirimidinski spojevi | |
| JP2017523169A5 (me) | ||
| JP2010524932A5 (me) | ||
| AR073760A1 (es) | Derivados heterociclicos y metodos de uso de los mismos | |
| HRP20170654T1 (hr) | Makrociklički deaza-purinoni za liječenje virusnih infekcija | |
| HRP20150977T1 (hr) | C-28 amidi modificiranih derivata c-3 betulinske kiseline kao inhibitori sazrijevanja hiv-a | |
| HRP20201023T1 (hr) | Dioksilan analozi uridina za liječenje raka | |
| HRP20150725T1 (hr) | Kondenzirani imidazolilimidazoli kao antivirusni spojevi | |
| NO20062758L (no) | Polycykliske midler for behandling av respiratorisk syncytial virus infeksjoner | |
| SI2738156T1 (en) | TETRACYCLINE COMPOSITE SUBSTITUTED WITH 9-AMINOMETHYL | |
| EP2041159B8 (en) | Macrocyclic compounds as antiviral agents | |
| HRP20130202T1 (hr) | Spojevi imidazo[1,2-a] pirazina za lijeäśenje virusnih infekcija kao što je hepatitis | |
| HRP20161125T1 (hr) | Makrociklički purini za liječenje virusnih infekcija | |
| CO6230992A2 (es) | Aril fosforamidatos de nucleosido y su uso como agentes antivirales para el tratamiento del virus de la hepatitis c | |
| HRP20160083T1 (hr) | Makrocikliäśki inhibitori serinske proteaze virusa hepatitisa c izvedeni iz prolina | |
| AR081830A1 (es) | Activadores de guanilato ciclasa soluble, composiciones farmaceuticas que los comprenden y sus usos | |
| AR046297A1 (es) | Inhibidores de la dpp - iv metodos para prepararlos y composiciones farmaceuticas que los contienen como agente activo | |
| HRP20220899T1 (hr) | Spojevi policikličkog karbamoilpiridona i njihova farmaceutska uporaba | |
| JP2015504081A5 (me) |